A Nature paper examines real-world results when GLP-1 therapy is delivered to women mainly through a digital care model.
Recap by typeshit. Full story at Nature.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Foundayo prescriptions rose from 57,920 the week before in its 27th week on sale. Oral Wegovy still leads on volume but fell from about 180K.
The once-weekly autoinjector is cleared for type 2 diabetes, overweight and obesity. Lilly never officially sold Mounjaro in Russia, and its rights there ended in November 2024.
Loading…